Nicox
en
fr
Toggle Menu
About Us
Visible Science
Leadership Team
Board of Directors
Partnerships
Portfolio and Disease Areas
Nicox’s innovative portfolio
Disease focus areas
Our portfolio at a glance
Nitric Oxide Donation
Publications
Investors
Stock Information
Financial and Regulatory Information
Shareholder Meetings
Corporate Presentation
Questions & Answers
Corporate Governance
News and Events
Press Releases
Events and Conferences
Videos
Contact Us
Contact Details
Main subsidiaries
Job opportunities
Email alerts
Nicox resubmits AC-170 (ZERVIATE1) NDA to the U.S. FDA
March 9, 2017
← Back to blog page
Cookies
By continuing to use this website, you agree to our
Cookie Policy
.
Accept
